BSH 2023 | Novel options for patients with CLL who relapse after treatment with BTK inhibitors and venetoclax

So patients that have CLL who require therapy, we’ve moved away from chemoimmunotherapy into this era of targeted therapies. Currently, how we sequence targeted therapies is still a point of discussion in conferences in general. But broadly speaking, whether you give a BTK inhibitor, first of all, or a venetoclax-based regimen, many patients will eventually progress through both options and then what do we do? So, with many of the regimens we give, there are fixed-duration therapies. So, depending on the nuances of the individual case, we may think about repeating some of those therapies. So, if patients have progressed on a venetoclax-based therapy, but it was a fixed-duration therapy, certainly in the UK, we have the option to potentially give another fixed-duration therapy depending on how much of an effect they had with it initially. But when patients we believe won’t benefit from those therapies that we’ve had for a number of years, we are looking to the trials that are showing great efficacy and it is exciting to see the data from the non-covalent BTK inhibitors such as pirtobrutinib and there are others, and BTK degraders which are exciting to see and then also kind of earlier in the development, it’ll be interesting to see how other targeted therapies and cellular therapies affect this space as well. So, it’ll be interesting over the next few years to see how this field and treatment landscape changes.